Access to anti-retroviral drugs, male in Singapore

Singapore: Access to anti-retroviral drugs, male was 86.0% in 2023. ◆ Volatile

Latest (2023)
86.0%
Change on year
up 1.2%
World rank
30th
of 141 countries
All-time high
86.0%
in 2023
All-time low
8.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, male in Singapore, 2000–2023

0204060802000201120232000: 8 %2001: 8 %2002: 9 %2003: 9 %2004: 10 %2005: 13 %2006: 20 %2007: 27 %2008: 36 %2009: 45 %2010: 53 %2011: 59 %2012: 63 %2013: 66 %2014: 73 %2015: 76 %2016: 77 %2017: 81 %2018: 81 %2019: 83 %2020: 85 %2021: 85 %2022: 85 %2023: 86 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, male in Singapore stood at 86.0%. That is the highest value across all 24 years on record.

The figure is up 1.2% on the previous year and up 30.3% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Singapore peaked at 86.0% in 2023 and was at its lowest, 8.0%, in 2000.

That places Singapore 30th out of 141 countries with data for 2023, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Singapore, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Singapore, 2000 to 2023.
Year % Change
2000 8.0%
2001 8.0% +0.0%
2002 9.0% +12.5%
2003 9.0% +0.0%
2004 10.0% +11.1%
2005 13.0% +30.0%
2006 20.0% +53.8%
2007 27.0% +35.0%
2008 36.0% +33.3%
2009 45.0% +25.0%
2010 53.0% +17.8%
2011 59.0% +11.3%
2012 63.0% +6.8%
2013 66.0% +4.8%
2014 73.0% +10.6%
2015 76.0% +4.1%
2016 77.0% +1.3%
2017 81.0% +5.2%
2018 81.0% +0.0%
2019 83.0% +2.5%
2020 85.0% +2.4%
2021 85.0% +0.0%
2022 85.0% +0.0%
2023 86.0% +1.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 18.5% 8.0% 45.0% 10
2010s 71.2% 53.0% 83.0% 10
2020s 85.2% 85.0% 86.0% 4

Countries ranked near Singapore

  1. 27 Ecuador 87.0% compare
  2. 27 Haiti 87.0% compare
  3. 27 Slovenia 87.0% compare
  4. 30 Liberia 86.0% compare
  5. 30 Thailand 86.0% compare
  6. 30 Togo 86.0% compare

See the full ranking of 160 places →

More gender data for Singapore

All data for Singapore →

Frequently asked questions

What is access to anti-retroviral drugs, male in Singapore?
Access to anti-retroviral drugs, male in Singapore was 86.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Singapore?
The highest recorded value was 86.0% in 2023.
What is the lowest access to anti-retroviral drugs, male recorded in Singapore?
The lowest recorded value was 8.0% in 2000.
How does Singapore rank for access to anti-retroviral drugs, male?
Singapore ranks 30th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, male rising or falling in Singapore?
Over the last ten years it is up 30.3%. The long-run trend across the full record is volatile.
Where does this Singapore data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Singapore. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/singapore/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/singapore/">Access to anti-retroviral drugs, male in Singapore</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.